dimenhydrinate Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
N-methylated xanthine derivatives	901	523-87-5

Description:

Molecule	Description
Synonyms: dimenhydrinate andramine chloranautine diamarin diphenhydramine 8-chlorotheophyllinate diphenhydrinate dramamine menhydrinate theohydramine	A drug combination that contains diphenhydramine and theophylline. It is used for treating VERTIGO, MOTION SICKNESS, and NAUSEA associated with PREGNANCY. Molecular weight: 469.97 Formula: C24H28ClN5O3 CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

dimenhydrinate
andramine
chloranautine
diamarin
diphenhydramine 8-chlorotheophyllinate
diphenhydrinate
dramamine
menhydrinate
theohydramine

A drug combination that contains diphenhydramine and theophylline. It is used for treating VERTIGO, MOTION SICKNESS, and NAUSEA associated with PREGNANCY.

Molecular weight: 469.97
Formula: C24H28ClN5O3
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
May 31, 1972	FDA	ALRA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Urine abnormality	398.39	15.63	149	31979	6311	53310627
Lymphocyte count decreased	319.15	15.63	203	31925	27849	53289089
Urine leukocyte esterase positive	265.58	15.63	90	32038	2846	53314092
Blood urine present	194.38	15.63	113	32015	13172	53303766
Red blood cells urine positive	193.31	15.63	71	32057	2853	53314085
White blood cells urine positive	186.11	15.63	78	32050	4467	53312471
Urinary sediment present	166.46	15.63	58	32070	1996	53314942
Enthesopathy	165.26	15.63	80	32048	6431	53310507
Blood parathyroid hormone decreased	140.65	15.63	71	32057	6247	53310691
Urine ketone body present	139.52	15.63	53	32075	2341	53314597
Tongue disorder	138.66	15.63	79	32049	8862	53308076
Tenosynovitis	133.49	15.63	80	32048	9859	53307079
Flushing	131.35	15.63	186	31942	70414	53246524
Urine analysis abnormal	128.61	15.63	60	32068	4440	53312498
Red blood cell sedimentation rate	125.24	15.63	52	32076	2907	53314031
Crystal urine present	125.17	15.63	43	32085	1417	53315521
Panniculitis	123.75	15.63	70	32058	7744	53309194
Granuloma skin	117.90	15.63	59	32069	5095	53311843
Red cell distribution width increased	112.30	15.63	69	32059	8891	53308047
Haemoglobin urine present	110.44	15.63	34	32094	785	53316153
Skin necrosis	109.08	15.63	72	32056	10500	53306438
Chest discomfort	107.11	15.63	205	31923	99490	53217448
Death	106.64	15.63	41	32087	357191	52959747
Rheumatoid nodule	101.55	15.63	72	32056	11792	53305146
Aplastic anaemia	99.02	15.63	62	32066	8259	53308679
Culture urine positive	93.97	15.63	45	32083	3530	53313408
Nausea	93.58	15.63	774	31354	755317	52561621
Bacterial test positive	90.61	15.63	49	32079	4964	53311974
Ulcer	85.28	15.63	82	32046	20537	53296401
Alanine aminotransferase abnormal	82.81	15.63	42	32086	3731	53313207
Bacterial test	81.11	15.63	30	32098	1229	53315709
Eosinophil count increased	79.20	15.63	57	32071	9555	53307383
Feeling hot	78.03	15.63	110	32018	41434	53275504
Tendonitis	76.77	15.63	71	32057	16935	53300003
Lymphocyte percentage decreased	72.11	15.63	35	32093	2828	53314110
Specific gravity urine decreased	71.87	15.63	23	32105	605	53316333
Fear of injection	69.93	15.63	43	32085	5546	53311392
Eosinophil percentage increased	68.96	15.63	25	32103	967	53315971
C-reactive protein abnormal	68.17	15.63	81	32047	25789	53291149
Monocyte percentage increased	66.73	15.63	25	32103	1062	53315876
Blood creatinine decreased	65.20	15.63	40	32088	5138	53311800
Completed suicide	64.26	15.63	5	32123	138196	53178742
Hypercalcaemia	63.77	15.63	76	32052	24272	53292666
Basal cell carcinoma	62.70	15.63	74	32054	23395	53293543
Mean cell haemoglobin concentration increased	60.59	15.63	19	32109	467	53316471
Infusion site pain	60.51	15.63	53	32075	11780	53305158
Body temperature increased	60.33	15.63	86	32042	32713	53284225
Neutrophil percentage increased	60.27	15.63	31	32097	2835	53314103
Neovascularisation	59.16	15.63	20	32108	627	53316311
Blood uric acid decreased	57.45	15.63	20	32108	686	53316252
Insomnia	55.95	15.63	242	31886	186830	53130108
Product dose omission issue	55.44	15.63	23	32105	191597	53125341
Monocyte count decreased	55.26	15.63	26	32102	1960	53314978
Blood pressure fluctuation	55.21	15.63	86	32042	35384	53281554
Gangrene	54.68	15.63	35	32093	4842	53312096
Urticaria	53.76	15.63	192	31936	135693	53181245
Arterial occlusive disease	53.57	15.63	35	32093	5014	53311924
Oropharyngeal pain	53.08	15.63	137	31991	81131	53235807
Intestinal pseudo-obstruction	51.99	15.63	19	32109	752	53316186
Poor venous access	51.65	15.63	45	32083	9930	53307008
Loss of personal independence in daily activities	51.18	15.63	123	32005	69692	53247246
Heart rate increased	50.94	15.63	136	31992	82179	53234759
Alveolitis	50.27	15.63	27	32101	2697	53314241
Mean cell haemoglobin decreased	49.95	15.63	29	32099	3368	53313570
Drug eruption	49.43	15.63	68	32060	25026	53291912
Haematocrit decreased	47.95	15.63	83	32045	37248	53279690
Rash pruritic	47.82	15.63	98	32030	49912	53267026
Red blood cell count decreased	47.66	15.63	81	32047	35822	53281116
Red cell distribution width decreased	46.61	15.63	19	32109	1013	53315925
Oesophageal spasm	46.13	15.63	25	32103	2543	53314395
Blood thyroid stimulating hormone increased	45.83	15.63	35	32093	6417	53310521
Headache	45.41	15.63	508	31620	536313	52780625
Protein urine present	45.37	15.63	33	32095	5621	53311317
Alanine aminotransferase increased	44.33	15.63	142	31986	94953	53221985
Creatinine urine decreased	43.40	15.63	12	32116	187	53316751
Arteriovenous fistula occlusion	43.36	15.63	14	32114	379	53316559
Blue toe syndrome	42.35	15.63	14	32114	409	53316529
Body temperature decreased	42.06	15.63	51	32077	16576	53300362
Acute kidney injury	41.81	15.63	55	32073	253813	53063125
Red blood cell sedimentation rate increased	40.86	15.63	66	32062	27991	53288947
Red blood cells urine	40.73	15.63	14	32114	462	53316476
Blood thyroid stimulating hormone decreased	40.52	15.63	28	32100	4399	53312539
Heart sounds	39.13	15.63	14	32114	521	53316417
Drug ineffective	38.93	15.63	311	31817	816934	52500004
Drug interaction	38.75	15.63	45	32083	219284	53097654
Leukocyturia	38.73	15.63	17	32111	1090	53315848
Specific gravity urine increased	38.30	15.63	11	32117	198	53316740
Thrombocytopenia	37.98	15.63	18	32110	138709	53178229
Urine leukocyte esterase	37.77	15.63	10	32118	131	53316807
Bradycardia	37.67	15.63	111	32017	70945	53245993
Skin ulcer	37.18	15.63	73	32055	36046	53280892
Hyponatraemia	36.67	15.63	10	32118	108597	53208341
Cardiac failure congestive	36.51	15.63	6	32122	92751	53224187
Chills	36.32	15.63	142	31986	104706	53212232
Tachycardia	36.23	15.63	145	31983	108067	53208871
C-reactive protein increased	35.94	15.63	106	32022	67780	53249158
Neutrophil count increased	35.58	15.63	45	32083	15265	53301673
Myelocyte count increased	35.35	15.63	12	32116	381	53316557
Erythema	35.23	15.63	187	31941	156782	53160156
Nitrite urine present	35.16	15.63	15	32113	897	53316041
Multiple sclerosis relapse	35.01	15.63	81	32047	44772	53272166
Heart rate decreased	34.84	15.63	72	32056	36875	53280063
Gastric disorder	34.80	15.63	64	32064	30101	53286837
Oesophageal pain	34.63	15.63	22	32106	3004	53313934
Red blood cell count increased	34.38	15.63	21	32107	2676	53314262
Blood pressure increased	34.06	15.63	171	31957	140308	53176630
Infusion related reaction	33.79	15.63	184	31944	155773	53161165
Toxicity to various agents	33.72	15.63	50	32078	219548	53097390
Oedema peripheral	33.57	15.63	32	32096	170755	53146183
Prolonged expiration	33.29	15.63	13	32115	619	53316319
Confusional state	33.07	15.63	41	32087	194180	53122758
Thyroxine free increased	32.62	15.63	14	32114	850	53316088
Mean cell haemoglobin concentration decreased	32.35	15.63	21	32107	2976	53313962
Joint injury	32.20	15.63	52	32076	22048	53294890
Mean cell volume decreased	31.57	15.63	20	32108	2717	53314221
Blood pressure systolic increased	31.36	15.63	67	32061	35110	53281828
Tri-iodothyronine free decreased	31.14	15.63	10	32118	266	53316672
Paradoxical drug reaction	30.36	15.63	21	32107	3304	53313634
pH urine increased	30.16	15.63	10	32118	295	53316643
Crystalluria	30.11	15.63	11	32117	435	53316503
Stress	30.08	15.63	89	32039	56995	53259943
Swelling	29.84	15.63	43	32085	191062	53125876
Cerebrovascular accident	29.79	15.63	13	32115	105161	53211777
Urine oxalate increased	29.06	15.63	9	32119	212	53316726
Band neutrophil percentage increased	28.86	15.63	9	32119	217	53316721
Gingival bleeding	28.32	15.63	36	32092	12272	53304666
Rhinorrhoea	27.73	15.63	83	32045	53495	53263443
Injection site pain	27.69	15.63	17	32111	113374	53203564
Injection site extravasation	27.45	15.63	28	32100	7524	53309414
Inflammation	27.23	15.63	86	32042	57050	53259888
Psoriatic arthropathy	27.19	15.63	77	32051	48113	53268825
Myelocyte percentage increased	26.83	15.63	8	32120	165	53316773
Throat irritation	26.71	15.63	59	32069	31622	53285316
Wound	26.44	15.63	11	32117	91546	53225392
Alopecia	25.90	15.63	65	32063	234518	53082420
Psoriasis	25.90	15.63	10	32118	87079	53229859
Neuropathy peripheral	25.86	15.63	15	32113	103172	53213766
Thyroid disorder	25.76	15.63	36	32092	13437	53303501
Cardiac failure	25.30	15.63	10	32118	85834	53231104
Band sensation	24.96	15.63	11	32117	712	53316226
Angina pectoris	24.79	15.63	54	32074	28671	53288267
Migraine	24.73	15.63	105	32023	80312	53236626
Renal failure	24.69	15.63	21	32107	118431	53198507
Band neutrophil count increased	24.61	15.63	9	32119	357	53316581
Aspartate aminotransferase increased	24.53	15.63	108	32020	83921	53233017
Bulimia nervosa	24.46	15.63	10	32118	537	53316401
Monocyte count increased	24.24	15.63	23	32105	5662	53311276
Urinary retention	23.99	15.63	53	32075	28413	53288525
Disease progression	23.90	15.63	16	32112	101904	53215034
Teratoma benign	23.54	15.63	6	32122	67	53316871
Seizure	23.47	15.63	26	32102	129483	53187455
Mean cell haemoglobin increased	23.03	15.63	15	32113	2137	53314801
Retinal depigmentation	22.94	15.63	8	32120	276	53316662
CFTR gene mutation	22.71	15.63	6	32122	78	53316860
Hyperkalaemia	22.52	15.63	3	32125	54253	53262685
Infusion site extravasation	22.46	15.63	23	32105	6209	53310729
Dizziness	22.34	15.63	331	31797	371928	52945010
Paranasal cyst	22.28	15.63	8	32120	301	53316637
Vascular malformation	22.23	15.63	8	32120	303	53316635
Drug abuse	22.18	15.63	6	32122	65520	53251418
Renal pain	21.28	15.63	22	32106	6005	53310933
Creatinine urine increased	21.22	15.63	7	32121	203	53316735
Injection site erythema	21.17	15.63	10	32118	77239	53239699
Palpitations	20.98	15.63	119	32009	102229	53214709
Infusion site discomfort	20.82	15.63	10	32118	789	53316149
Hypoglycaemia	20.75	15.63	5	32123	59008	53257930
Cardio-respiratory arrest	20.62	15.63	5	32123	58753	53258185
Nasopharyngitis	20.46	15.63	191	31937	192104	53124834
Colitis microscopic	20.00	15.63	23	32105	7071	53309867
Electrocardiogram QRS complex abnormal	19.68	15.63	7	32121	256	53316682
Gestational hypertension	19.59	15.63	14	32114	2319	53314619
Mastoiditis	19.53	15.63	10	32118	906	53316032
Osteoarthritis	19.51	15.63	9	32119	70477	53246461
Fumbling	19.23	15.63	6	32122	145	53316793
Immune thrombocytopenia	19.22	15.63	26	32102	9412	53307526
Multiple organ dysfunction syndrome	19.03	15.63	5	32123	55672	53261266
Thyroid stimulating immunoglobulin	18.99	15.63	5	32123	64	53316874
Skin papilloma	18.96	15.63	18	32110	4433	53312505
Lipaemic index score	18.58	15.63	5	32123	70	53316868
Klebsiella test positive	18.40	15.63	10	32118	1023	53315915
Mean cell volume increased	18.22	15.63	15	32113	3064	53313874
Productive cough	18.16	15.63	75	32053	56654	53260284
Vitamin B12 decreased	18.16	15.63	15	32113	3077	53313861
Impaired healing	18.08	15.63	8	32120	64197	53252741
Dry throat	17.96	15.63	20	32108	5936	53311002
Feeling abnormal	17.86	15.63	141	31987	135160	53181778
Wrong technique in product usage process	17.67	15.63	7	32121	60025	53256913
Immature granulocyte count increased	17.64	15.63	7	32121	348	53316590
Lymphoedema	17.29	15.63	25	32103	9628	53307310
Anaemia	17.23	15.63	97	32031	276621	53040317
Gastrointestinal haemorrhage	17.04	15.63	14	32114	80316	53236622
Limbal swelling	17.01	15.63	4	32124	31	53316907
Interstitial lung disease	16.99	15.63	7	32121	58615	53258323
Rhabdomyolysis	16.93	15.63	3	32125	43920	53273018
Endometrial ablation	16.86	15.63	9	32119	888	53316050
Thyroid cyst	16.67	15.63	8	32120	630	53316308
Granuloma	16.65	15.63	17	32111	4571	53312367
White blood cell count decreased	16.58	15.63	130	31998	124345	53192593
Infusion site scar	16.58	15.63	6	32122	231	53316707
Blood luteinising hormone decreased	16.57	15.63	4	32124	35	53316903
Infection	16.55	15.63	51	32077	172154	53144784
Rales	16.48	15.63	26	32102	10806	53306132
Anxiety	16.45	15.63	186	31942	196518	53120420
Intestinal polyp	16.43	15.63	10	32118	1266	53315672
Cough	16.40	15.63	231	31897	256662	53060276
Urethral pain	16.12	15.63	6	32122	250	53316688
Heart rate irregular	16.11	15.63	37	32091	20347	53296591
Angioedema	15.95	15.63	3	32125	42073	53274865
Large intestinal ulcer haemorrhage	15.90	15.63	5	32123	124	53316814
Ill-defined disorder	15.86	15.63	5	32123	49439	53267499
Hypokalaemia	15.77	15.63	21	32107	96496	53220442
Deep vein thrombosis	15.74	15.63	16	32112	82897	53234041
Change in seizure presentation	15.71	15.63	6	32122	269	53316669
Septic shock	15.65	15.63	9	32119	62220	53254718
Arthritis	15.64	15.63	98	32030	87200	53229738

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Enthesopathy	152.98	18.38	51	8662	3512	32501301
Tenosynovitis	149.72	18.38	51	8662	3752	32501061
Aplastic anaemia	140.17	18.38	58	8655	7315	32497498
C-reactive protein abnormal	120.81	18.38	50	8663	6306	32498507
Tongue disorder	117.06	18.38	45	8668	4679	32500134
Victim of child abuse	99.56	18.38	26	8687	757	32504056
Synovitis	98.01	18.38	51	8662	10827	32493986
Erythema	94.91	18.38	114	8599	82991	32421822
Alanine aminotransferase abnormal	93.74	18.38	34	8679	3006	32501807
Tendonitis	90.47	18.38	45	8668	8690	32496123
Respiratory depression	75.61	18.38	46	8667	13165	32491648
Psoriatic arthropathy	62.98	18.38	46	8667	17814	32486999
Loss of personal independence in daily activities	62.19	18.38	54	8659	26779	32478034
Epidural lipomatosis	60.88	18.38	17	8696	640	32504173
Febrile neutropenia	54.39	18.38	107	8606	119459	32385354
Drug dependence	53.89	18.38	47	8666	23437	32481376
Aspartate aminotransferase increased	49.42	18.38	74	8639	66355	32438458
Lymphocyte percentage decreased	47.70	18.38	19	8694	2168	32502645
Nausea	47.26	18.38	190	8523	320659	32184154
Urine abnormality	47.03	18.38	18	8695	1847	32502966
Alanine aminotransferase increased	46.78	18.38	79	8634	78400	32426413
Platelet transfusion	44.33	18.38	15	8698	1079	32503734
Death	42.58	18.38	25	8688	382492	32122321
Heart rate irregular	42.39	18.38	33	8680	14045	32490768
Red blood cell sedimentation rate	41.82	18.38	12	8701	499	32504314
Treatment failure	41.81	18.38	52	8661	39111	32465702
Blood pressure fluctuation	41.63	18.38	38	8675	20097	32484716
Child abuse	41.23	18.38	11	8702	348	32504465
Lymphocyte count decreased	40.08	18.38	38	8675	21081	32483732
Granuloma skin	39.34	18.38	12	8701	618	32504195
Limb malformation	37.12	18.38	11	8702	513	32504300
Foetal exposure during pregnancy	36.55	18.38	50	8663	41251	32463562
Product prescribing error	36.51	18.38	35	8678	19682	32485131
Blood parathyroid hormone decreased	36.30	18.38	12	8701	803	32504010
Neutrophil percentage increased	35.82	18.38	15	8698	1944	32502869
Congenital skin dimples	33.40	18.38	8	8705	162	32504651
Juvenile idiopathic arthritis	32.45	18.38	13	8700	1505	32503308
C-reactive protein increased	32.12	18.38	51	8662	48051	32456762
Mucosal inflammation	31.91	18.38	42	8671	33392	32471421
Panniculitis	31.51	18.38	12	8701	1214	32503599
Product use issue	29.93	18.38	52	8661	52725	32452088
Vomiting	28.78	18.38	132	8581	235425	32269388
Drug intolerance	27.84	18.38	49	8664	50186	32454627
Drug hypersensitivity	27.81	18.38	61	8652	73339	32431474
pH urine increased	27.76	18.38	6	8707	75	32504738
Epispadias	27.70	18.38	7	8706	178	32504635
Transfusion	27.35	18.38	20	8693	7748	32497065
Rheumatoid nodule	25.25	18.38	12	8701	2095	32502718
Contraindicated product administered	24.76	18.38	28	8685	19048	32485765
Headache	24.72	18.38	111	8602	196086	32308727
White blood cells urine positive	24.21	18.38	10	8703	1252	32503561
Specific gravity urine increased	24.20	18.38	6	8707	141	32504672
Off label use	23.40	18.38	151	8562	306169	32198644
Urine leukocyte esterase positive	22.04	18.38	7	8706	412	32504401
Urine ketone body present	21.80	18.38	9	8704	1125	32503688
Red blood cell elliptocytes present	21.64	18.38	5	8708	86	32504727
Pyloric stenosis	21.13	18.38	8	8705	797	32504016
Inappropriate schedule of product administration	20.76	18.38	41	8672	45784	32459029
Band neutrophil percentage increased	20.52	18.38	5	8708	109	32504704

Pharmacologic Action:

Source	Code	Description
ATC	R06AA11	RESPIRATORY SYSTEM ANTIHISTAMINES FOR SYSTEMIC USE ANTIHISTAMINES FOR SYSTEMIC USE Aminoalkyl ethers
CHEBI has role	CHEBI:37955	H1-receptor blockers
CHEBI has role	CHEBI:50919	antiemetico
MeSH PA	D000932	Antiemetics
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D005765	Gastrointestinal Agents
MeSH PA	D018494	Histamine Agents
MeSH PA	D006633	Histamine Antagonists
MeSH PA	D006634	Histamine H1 Antagonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018373	Peripheral Nervous System Agents

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Nausea and vomiting	indication	16932000
Motion sickness	indication	37031009	DOID:2951
Vertigo	indication	399153001
Vomiting	indication	422400008
Nausea	indication	422587007
Prevention of Motion Sickness	indication
Prevention of Nausea and Vomiting	indication
Ménière's disease	off-label use	13445001	DOID:9849
Ocular hypertension	contraindication	4210003	DOID:9282
Hypophosphatemia	contraindication	4996001
Alcoholism	contraindication	7200002
Peptic ulcer	contraindication	13200003	DOID:750
Myocardial infarction	contraindication	22298006	DOID:5844
Hyperthyroidism	contraindication	34486009	DOID:7998
Hypertensive disorder	contraindication	38341003	DOID:10763
Low blood pressure	contraindication	45007003
Blood coagulation disorder	contraindication	64779008	DOID:1247
Diabetes mellitus	contraindication	73211009	DOID:9351
Hyperglycemia	contraindication	80394007	DOID:4195
Chronic idiopathic constipation	contraindication	82934008
Gout	contraindication	90560007	DOID:13189
Liver function tests abnormal	contraindication	166603001
Arterial hemorrhage	contraindication	234003006
Disease of liver	contraindication	235856003	DOID:409
Bladder outflow obstruction	contraindication	236645006
Pyloric obstruction	contraindication	244815007
Benign prostatic hyperplasia	contraindication	266569009
Retention of urine	contraindication	267064002
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Acute coronary syndrome	contraindication	394659003
Disorder of coronary artery	contraindication	414024009

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN	ANTAGONIST	Ki	7.43	DRUG MATRIX	CHEMBL
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	6.31	DRUG MATRIX
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	5.70	DRUG MATRIX
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	6.70	DRUG MATRIX
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	5.96	DRUG MATRIX
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	6.48	DRUG MATRIX
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	5.60	DRUG MATRIX
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		Ki	6.96	DRUG MATRIX
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		Ki	6.79	DRUG MATRIX
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN		Ki	7.02	DRUG MATRIX
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	7.10	DRUG MATRIX
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	6.64	DRUG MATRIX
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	5.75	DRUG MATRIX
Cytochrome P450 2D6	Enzyme	P10635	CP2D6_HUMAN		IC50	5.82	DRUG MATRIX
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	5.79	DRUG MATRIX
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN		Ki	5.85	DRUG MATRIX

External reference:

ID	Source
4018048	VUID
N0000146389	NUI
D00520	KEGG_DRUG
4018048	VANDF
C0012381	UMLSCUI
CHEBI:4604	CHEBI
CHEMBL1200406	ChEMBL_ID
DB00985	DRUGBANK_ID
D004111	MESH_DESCRIPTOR_UI
10660	PUBCHEM_CID
61	INN_ID
JB937PER5C	UNII
151666	RXNORM
1568	MMSL
4605	MMSL
6646	MMSL
d00861	MMSL
003371	NDDF
387469006	SNOMEDCT_US
81073007	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Wal-Dram	HUMAN OTC DRUG LABEL	1	0363-0198	TABLET	50 mg	ORAL	OTC MONOGRAPH FINAL	15 sections
Wal-Dram	HUMAN OTC DRUG LABEL	1	0363-0198	TABLET	50 mg	ORAL	OTC MONOGRAPH FINAL	15 sections
Motion Sickness Relief	HUMAN OTC DRUG LABEL	1	0363-1980	TABLET	50 mg	ORAL	OTC monograph final	15 sections
Motion Sickness Relief	HUMAN OTC DRUG LABEL	1	0363-1980	TABLET	50 mg	ORAL	OTC monograph final	15 sections
Driminate	HUMAN OTC DRUG LABEL	1	0904-2051	TABLET	50 mg	ORAL	OTC monograph final	15 sections
Driminate	HUMAN OTC DRUG LABEL	1	0904-2051	TABLET	50 mg	ORAL	OTC monograph final	15 sections
Dimenhydrinate	HUMAN OTC DRUG LABEL	1	0904-6772	TABLET	50 mg	ORAL	OTC monograph final	16 sections
PhysiciansCare DimenhydrinateMotion Sickness Relief	HUMAN OTC DRUG LABEL	1	0924-1006	TABLET, COATED	50 mg	ORAL	OTC monograph final	16 sections
Dimenhydrinate	HUMAN OTC DRUG LABEL	1	0924-1007	TABLET	50 mg	ORAL	OTC monograph final	17 sections
Motion Sickness	HUMAN OTC DRUG LABEL	1	11673-198	TABLET	50 mg	ORAL	OTC MONOGRAPH FINAL	15 sections
Motion Sickness	HUMAN OTC DRUG LABEL	1	11673-198	TABLET	50 mg	ORAL	OTC MONOGRAPH FINAL	15 sections
Motion Sickness Relief	HUMAN OTC DRUG LABEL	1	11822-0198	TABLET	50 mg	ORAL	OTC monograph final	15 sections
Motion Sickness Relief	HUMAN OTC DRUG LABEL	1	11822-0198	TABLET	50 mg	ORAL	OTC monograph final	15 sections
Dramamine	HUMAN OTC DRUG LABEL	1	29485-1216	TABLET, CHEWABLE	50 mg	ORAL	OTC monograph final	16 sections
Dramamine	HUMAN OTC DRUG LABEL	1	29485-6925	TABLET, CHEWABLE	50 mg	ORAL	OTC monograph final	16 sections
Dramamine	HUMAN OTC DRUG LABEL	1	29485-8048	TABLET, CHEWABLE	50 mg	ORAL	OTC monograph final	16 sections
Motion Sickness Relief	HUMAN OTC DRUG LABEL	1	36800-930	TABLET	50 mg	ORAL	OTC monograph final	15 sections
Motion Sickness Relief	HUMAN OTC DRUG LABEL	1	36800-930	TABLET	50 mg	ORAL	OTC monograph final	15 sections
Motion Sickness Relief	HUMAN OTC DRUG LABEL	1	46122-536	TABLET	50 mg	ORAL	OTC monograph final	15 sections
Motion Sickness Relief	HUMAN OTC DRUG LABEL	1	46122-536	TABLET	50 mg	ORAL	OTC monograph final	15 sections
Motion Sickness Relief	HUMAN OTC DRUG LABEL	1	49035-981	TABLET	50 mg	ORAL	OTC MONOGRAPH FINAL	15 sections
Motion Sickness Relief	HUMAN OTC DRUG LABEL	1	49035-981	TABLET	50 mg	ORAL	OTC MONOGRAPH FINAL	15 sections
DIMENHYDRINATE	HUMAN OTC DRUG LABEL	1	49483-352	TABLET, FILM COATED	50 mg	ORAL	OTC monograph final	11 sections
Airmit Ace	HUMAN OTC DRUG LABEL	1	49873-802	TABLET	25 mg	ORAL	OTC monograph final	12 sections
Motion Sickness	HUMAN OTC DRUG LABEL	1	50804-198	TABLET	50 mg	ORAL	OTC MONOGRAPH FINAL	15 sections
Motion Sickness	HUMAN OTC DRUG LABEL	1	50804-198	TABLET	50 mg	ORAL	OTC MONOGRAPH FINAL	15 sections
Motion Sickness Relief	HUMAN OTC DRUG LABEL	1	50844-199	TABLET	50 mg	ORAL	OTC monograph final	15 sections
Motion Sickness Relief	HUMAN OTC DRUG LABEL	1	50844-199	TABLET	50 mg	ORAL	OTC monograph final	15 sections
Motion Sickness	HUMAN OTC DRUG LABEL	1	59779-198	TABLET	50 mg	ORAL	OTC monograph final	15 sections
Motion Sickness	HUMAN OTC DRUG LABEL	1	59779-198	TABLET	50 mg	ORAL	OTC monograph final	15 sections